ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
TP53 pathway may play pivotal roles in the development of ovarian cancer and TP53 pathway may be a new target for the treatment of ovarian cancer.
|
29565482 |
2018 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Besides p53DeltaE6 and p53beta, we identified p53zeta, p53delta and p53varepsilon, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53delta expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032).
|
20101229 |
2010 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that COX-2 expression might play an important role in ovarian cancer development and that COX-2 expression in ovarian adenocarcinomas is frequently associated with p53 protein accumulation.
|
12469191 |
2003 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Additionally, combination treatment of p53 gene transduction and CDDP may be an effective therapeutic modality for ovarian cancer without wild-type p53 gene.
|
11774736 |
2001 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition to mutation of BRCA1, mutation of the p53 gene is often found in patients with inherited breast and ovarian cancer syndrome.
|
20046879 |
2009 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Transcriptional regulation of the c-H-ras1 gene by the P53 protein is implicated in the development of human endometrial and ovarian tumours.
|
9662334 |
1998 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Several studies have shown that TP53 is more frequently inactivated in BRCA1-associated tumors than in sporadic breast or ovarian cancer.
|
10580847 |
1999 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
|
25316818 |
2014 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The data presented here implicate the regulation of p53 subcellular localization and apoptosis by PARC as a contributing factor in CDDP resistance in OVCA cells and Ca(2+)/calpain in PARC post-translational processing and chemosensitivity.
|
22117079 |
2012 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the TP53 codon 72 genotypes may be considered as a molecular marker, contributing to a genetic profile for ovarian cancer in women.
|
16542834 |
2006 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer.
|
17968145 |
2007 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that intronic polymorphisms of the p53 gene modify the risk for ovarian cancer patients but not in carriers with BRCA1 or BRCA2 mutations.
|
10487631 |
1999 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We previously reported that targeting p53 for degradation by the human HPV E6 gene in the ovarian cancer cell line PA1 leads to an increase in the chemoresistant phenotype.
|
11791171 |
2002 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therefore, current estimates of TP53 alterations in ovarian cancer may be inaccurate.
|
9579562 |
1998 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these data suggest that at least in our patient cohort p53 and p73 expression levels are not correlated to malignant progression of ovarian cancer.
|
18039564 |
2008 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This represents the first attempt to define a genomic signature of TP53 mutation in ovarian cancer.
|
20504346 |
2010 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, there has been so far no report of nonviral vector-mediated p53 gene deliveries in ovarian cancer.
|
12893186 |
2003 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
|
27189670 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Preoperative findings of adnexal mass with serum p53 AAb are strongly suggestive of an aggressive invasive ovarian cancer.
|
11044359 |
2000 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that a germ line p53 mutation significantly enhanced DMBA-induced ovarian tumor development and progression.
|
18234966 |
2008 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.
|
8679443 |
1996 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
|
11595686 |
2001 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Patients with concomitantly high levels of PARP, FANCD2 and P53 protein expression are at increased risk of early ovarian cancer recurrence and platinum resistance.
|
22253870 |
2012 |